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Abstract    
There is an increase in the amount of  genetics research 
being conducted in both developed and limited resource 
countries.  Most of  this research is sponsored by developed 
countries.  There are concerns in limited resource countries 
on how the benefits from this research are currently being 
shared or will be shared in the future.  There is need for 
caution, to ensure that populations from limited resource 
countries are not exploited by being used as subjects in 
genetics research which is meant to benefit populations 
from developed countries.  This paper addresses the issue 
of  fairness in benefits sharing and argues for justice in the 
sharing of  both burdens and benefits of  genetics research. 
The paper responds to some of  the issues and arguments in 
recent literature on the meaning and limits of  the concept of  
benefit sharing in human genetics research.
Introduction  
While the greater majority of  genetics research studies are 
currently being conducted in and by developed countries, 
limited resource countries are currently also witnessing an 
increase in the amount of  genetics research being conducted 
on their populations.  This increase brings with it social, 
legal and ethical implications, and among them are the issues 
surrounding how the benefits of  this research are shared. 
Most of  the genetics research being conducted today focuses 
on diseases of  affluence whilst ignoring the diseases of  
poverty. 1   There are currently some debates going on the 
avoidance of  exploitation of  weaker parties in international 
research and we argue that international research will only 
continue to flourish based on cooperation, collaboration 
and respect of  limited resource country views and values 
by developed country counterparts.2  Limited resource 
countries continue to play an important role in research as 
they provide a fertile ground for clinical trials due to various 
reasons including the serious burden of  disease and ready 
availability of  willing volunteers. 
Defining benefit sharing
We outrightly acknowledge that this paper only deals 
with the issue of  benefits sharing from the point of  view 
of  health benefits.  We recognize that in human genetics 
research, there are other benefits such as profits, jobs and 
others.  We also note that there are other important issues 
that need attention such as ownership rights and other legal 
issues.  While we acknowledge their importance, we feel that 
the other issues are better off  being addressed by others who 
are competent to unpack the complications as well as the 
contradictions they bring about.   Shroeder defines benefit 
sharing as the action of  giving a portion of  advantages or 
profits derived from the use of  human genetic resources to 
those persons who would have provided those resources so 
as to achieve justice.3   Shroeder emphasises on the provision 
of  benefits to those who lack reasonable access to products 
and services resulting from the research without providing 
undue inducements.  This definition is adopted in this paper 
as it is very relevant to poor countries and communities 
which are easily tempted by the various inducements that 
may be offered in exchange for volunteering. 
Status of genetics research
Much of  the genetics research conducted in limited resource 
countries is  sponsored by agencies and governments from 
developed countries and most of  the studies are  meant to 
address problems of  people from these countries who can 
also afford the new genetic technologies.4    While limited 
resource countries are not directly involved in directing 
the research agenda in genetics research, they are acting as 
a rich source of  biological materials for genetics research. 
The current scenario prevails because developing countries 
face limitations in terms of  the financial and technological 
resources necessary to undertake such research.   
In order to illustrate this unfair situation, the term  “postal 
research” has since been coined to refer to studies where 
developing countries courier biological materials to the west. 
The term “parachute research” has been coined to refer to 
western researchers who travel to developing countries to 
collect biological samples and take them to their countries 
for analysis and the exploitation of  the research findings, 
never to be seen again in the developing country sites where 
they would have collected their specimens.  Several other 
terms have been developed to reflect this situation.  Other 
authors have even gone as far as describing a “biotechnology 
gold rush” in which the territory is the human body.5
While the genetics research stakeholders in the developed 
countries appear to be more organized in terms of  disease 
specific research foundations, disease associated advocacy 
groups and other structures which represent and serve the 
interests of  the various stakeholders in research, limited 
resource countries do not have such pronounced structures. 
Where such structures are in existence, they are still in their 
formative stages or they are sub-units of  mother bodies 
in rich countries, and hence they are not very influential in 
such decisions as the sharing of  benefits.  The major players 
when it comes to benefit sharing in developing regions are; 
the countries, institutions, researchers, research subjects and 
research ethics committees, which are a recent feature in 
most limited resource countries.  Limited resource country 
governments and institutions  have little or no budgets set 
aside for genetics research as they have to battle with the 
serious levels of  poverty.  
Levels of benefit sharing
The issue of  benefits sharing, can be looked at from two levels 
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; the micro level where one can focus directly on the research 
subject who directly participates in the research, as well as 
at the macro level, where one may focus on communities 
or countries that participate in research as well as the global 
situation  (limited resource and developed countries).  At the 
micro level, the issue of  benefit sharing can be looked at in 
terms of  the principle of  “compensation”.    The principle 
of  compensation can be viewed from two  different angles. 
Compensation may take the form of  a direct payment for 
participation.  Compensation may also take the form of  
participation in the eventual economic and other benefits. 
6 Compensation for participation is straight forward and 
easier to address as each subject is compensated for the time 
spent, the pain and other inconveniences.  The payment is 
made on the subject’s cooperation in a scientific programme. 
It may also be made on the sale of  the blood sample or 
other bodily tissues.    The UNESCO Sub-committee on 
Population Genetics, strongly emphasises that undue 
inducement through compensation is not and should never 
be encouraged.7
As regards participation in the eventual benefits, the 
Declaration of  Helsinki offers clear guidance especially 
for research conducted in the developing countries.  The 
year 2000 version of  the Declaration of  Helsinki states 
categorically that at the end of  any research study, every 
subject entered in the project should be assured of  the best 
proven prophylactic, diagnostic and therapeutic methods 
identified by that study.  The World Medical Assembly 
emphasizes that medical research is only justified if  there 
is a reasonable likelihood that the populations in which the 
research is carried out stands to benefit from the results of  
the research.8
One issue that arises when considering whether it is 
appropriate or not to conduct a specific study within a 
developing country is whether the intervention being 
studied is likely to be affordable to that country or not. 
Participants in the research may have a condition requiring 
ongoing treatment.  In such cases there is an obligation to 
continue to provide an intervention that has been shown to 
be effective to all participants?  Whose responsibility should 
it be?  Serious criticisms have thus been levelled against the 
Declaration of  Helsinki for emphasizing that at the end 
of  a study, every subject entered into the study should be 
assured of  access to the best proven prophylactic, diagnostic 
and therapeutic methods identified by that research.  The 
Nuffield Council on Bioethics notes that this may also be 
difficult to implement especially in relation to ongoing 
treatment for chronic diseases.9
The role of the Ethics Committees in benefits 
sharing
The National Bioethics Advisory Commission (NBAC) in 
its report even goes further to recommend that researchers 
should before initiation of  a research study, endeavour to 
secure access for all participants to effective treatment after 
the trial and that the lack of  any such arrangements should 
be justified to a research ethics committee (REC).10  The 
report also recommends that researchers should indicate in 
their proposals how they intend to make the intervention 
available to participants after the trial if  the intervention is 
proven successful.  It even goes further to recommend that 
researchers should justify to the REC why the research should 
be carried out in that country.  It is however important to note 
that the availability of  an intervention after trial depends on 
several factors including cost of  providing the intervention, 
supervising its administration, the necessary infrastructure 
required and others.  
As a further way of  ensuring that developing countries 
are not used as sites for research that is not of  relevance 
to them, the Council for International Organisations of  
the Medical Sciences Guidelines specifically state that all 
research that is conducted in developing countries and 
sponsored  by developed countries, should be of  relevance 
to the developing countries.11 The relevance of  the study to 
the country is a sure way of  ensuring that countries stand to 
benefit once their citizens participate as subjects of  genetics 
research.   It is however important to note that while relevance 
and benefit sharing are very important, it is very difficult to 
formulate guidelines which satisfactorily address the issue of  
benefit sharing.
Benefits from pharmacogenomics
Many hope that pharmacogenomics will change the face 
of  medicine by reducing the number of  people who die 
from adverse drug reactions each year and also by enabling 
identification of  the most efficacious drugs for individuals. 
Pharmacogenomics is the study of  how an individual’s 
genetic inheritance affects the body’s response to drugs. The 
term comes from the words pharmacology and genomics 
and is thus the intersection of  pharmaceuticals and genetics. 
According to its proponents, pharmacogenomics holds 
the promise that drugs might one day be tailor-made for 
individuals and adapted to each person’s own genetic make-
up, environment, diet, age, lifestyle, and state of  health. 
Understanding an individual’s genetic make-up is thought 
to be the key to creating personalized drugs with greater 
efficacy and safety. 12
Whilst a lot continues to be mentioned in glorifying 
pharmacogenomics, the question that however needs to 
be asked is whether developing countries will benefit from 
pharmacogenomics in the above ways.  Who will be the 
target of  drug production by pharmaceutical companies? 
Who will be left behind in new drug development?   Will 
developing countries health problems be addressed through 
pharmacogenomics?   Drug companies always think about 
maximizing their profits and are usually interested in catering 
for those diseases from which they can reap the most 
profits.
At the global level, the Human Genome Organisation Ethics 
Committee has issued some very important recommendations 
regarding benefit sharing, aimed at ensuring that developing 
countries, participate in sharing the benefits from genetics 
research.13  Some of  the recommendations with a bearing on 
benefit sharing include the following :
• All humanity (including developed countries) should share 
in and have access to the benefits of genetics research.
• Benefits should not be limited only to those individuals who 
participated in such research.
• There should be prior discussion with groups or communities on 
the issue of benefit sharing in this case RECs and community 
representatives.
• Even in the absence of profits, immediate health benefits as 
determined by the community needs should be provided.
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• At a minimum all research participants should receive 
information about general research outcomes and a general 
indication of appreciation.
• Profit making entities should dedicate a percentage of their 
annual net profits to health care infrastructure and/or 
humanitarian efforts.
The above recommendations are based on the simple 
fact that the human genome is the common heritage of  
humanity since all mankind share in essence the same 
gene.  The committee notes that currently there is a great 
inequality between rich and poor nations in the direction 
and priorities of  research and in the distribution and access 
to the benefits thereof, hence the recommendation that all 
countries should share in the benefits of  genetics research. 
The moral arguments that are highlighted by Kadri Simm 
of  duty not to exploit the vulnerable and duty to alleviate 
suffering, are very strong when one considers the history 
of  exploitation between the developed and limited resource 
countries.2  The arguments also hold when one considers the 
role the limited resource countries continue to play in further 
advancing the development of  developed countries through 
the provision of  cheap research specimens.  The argument 
about the special moral obligations of  medical enterprises is 
also very important considering that health problems are not 
contained by national or geographic boundaries.  Instead of  
leaving the private enterprises to play their role in medical 
research unchecked, we argue for the increased involvement 
of  the United Nations in topical areas such as genomics, 
cloning and others so as to deal with the selfish arguments 
as well as the contradictions that drive parties into different 
camps. 
Research Ethics Committees being the gatekeepers when 
it comes to health research, can play an important role of  
ensuring that the communities and individuals are not 
exploited in research.  More often, it is very difficult for 
a community to voice its concerns due to various reasons 
including lack of  appropriate structures for communication.1 
The ethics committees are made up of  various members, 
knowledgeable in research and other issues and can therefore 
serve as the voice of  the voiceless communities and 
individuals in developing countries.   We completely disagree 
with others who suggest that benefit sharing is conceptually 
problematic.  We argue that we need not only focus on profits 
but on ways of  ensuring that poor communities benefit after 
participating in genetic research in one way or the other. 
While we acknowledge the concept of  genetic solidarity as a 
moral ground for benefit sharing,5 we argue that developing 
countries and institutions need to come to the negotiating 
table with pride since they have a very useful resource in 
research - human beings that are willing to participate in 
research.  We note that where money is involved, it is easy 
to forget about solidarity in favour of  profits.   Others may 
want to look at arguments in support of  benefit sharing as 
encouraging bribery for people to participate in research. 5  We 
maintain that benefit sharing ensures that the disadvantaged 
at least benefit in some way from an activity in which they 
have participated in.
Conclusion
In this paper we take the view that at both the micro 
level and the macro level, compensation for participation 
in any commercially exploitable genetic research is the 
fairest thing to do and that this compensation should not 
only be in monetary terms but can also take the form of  
health benefits, technology transfer, scientific, technical and 
medical training, installation and ongoing maintenance of  
infrastructure such as laboratories, clinics, libraries and other 
facilities. We also argue that Research Ethics Committees in 
developing countries should be strengthened so that they 
can make informed decisions on sharing the benefits of  
research and other important issues.   We put forward that 
RECs should negotiate on behalf  of  their communities by 
ensuring that on granting permission to any genetics research 
projects that are commercially exploitable, they insist that 
this should be made clear at the outset to the participants 
and that this must be part of  the recruitment and informed 
consent process as well as the contracts between scientists 
from the developed countries and their counterparts from 
the developing countries.  We also put forward that RECs in 
developing countries should play the extra role of  ensuring 
that the researchers and their institutions negotiate these 
issues before research is performed on behalf  of  the research 
participants and their own countries. 
Developing country research participants should be given 
a voice in decisions affecting access and benefits from 
commercialized products.    This can only be achieved if  they 
are educated on genetics research and what the new research 
findings may mean to them.  Unless action is taken, it is likely 
that benefits from genetic research will only accrue to the rich 
nations and rich people – and this is but unfair.  Sharing the 
benefits of  genetics research is one sure way of  addressing 
the inequalities between the rich and poor nations. 
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